-
Something wrong with this record ?
Salicylanilide diethyl phosphates as potential inhibitors of some mycobacterial enzymes
M. Krátký, E. Novotná, S. Saxena, P. Yogeeswari, D. Sriram, M. Švarcová, J. Vinšová,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT13346
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2000
PubMed Central
from 2000
Europe PubMed Central
from 2000
ProQuest Central
from 2012-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2012-01-03
Medline Complete (EBSCOhost)
from 2012-01-01
Health & Medicine (ProQuest)
from 2012-01-01
Wiley-Blackwell Open Access Titles
from 2000
PubMed
25538961
DOI
10.1155/2014/703053
Knihovny.cz E-resources
- MeSH
- Antitubercular Agents chemistry MeSH
- Bacterial Proteins * antagonists & inhibitors chemistry MeSH
- Enzyme Inhibitors chemistry MeSH
- Mycobacterium tuberculosis enzymology MeSH
- Salicylanilides chemistry MeSH
- Molecular Docking Simulation * MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Antimycobacterially active salicylanilide diethyl phosphates were evaluated to identify their potential drug target(s) for the inhibition of several mycobacterial enzymes, including isocitrate lyase, L-alanine dehydrogenase (MtAlaDH), lysine ε-aminotransferase, chorismate mutase, and pantothenate synthetase. The enzymes are related to the nongrowing state of Mycobacterium tuberculosis. Salicylanilide diethyl phosphates represent new candidates with significant inhibitory activity especially against L-alanine dehydrogenase. The most active MtAlaDH inhibitor, 5-chloro-2-[(3-chlorophenyl)carbamoyl]phenyl diethyl phosphate, has an IC50 of 4.96 µM and the best docking results. Other mycobacterial enzymes were mostly inhibited by some derivatives but at higher concentrations; isocitrate lyase showed the highest resistance to salicylanilide diethyl phosphates.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000425
- 003
- CZ-PrNML
- 005
- 20181212134152.0
- 007
- ta
- 008
- 160108s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2014/703053 $2 doi
- 035 __
- $a (PubMed)25538961
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Krátký, Martin $u Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. $7 jo2017947786
- 245 10
- $a Salicylanilide diethyl phosphates as potential inhibitors of some mycobacterial enzymes / $c M. Krátký, E. Novotná, S. Saxena, P. Yogeeswari, D. Sriram, M. Švarcová, J. Vinšová,
- 520 9_
- $a Antimycobacterially active salicylanilide diethyl phosphates were evaluated to identify their potential drug target(s) for the inhibition of several mycobacterial enzymes, including isocitrate lyase, L-alanine dehydrogenase (MtAlaDH), lysine ε-aminotransferase, chorismate mutase, and pantothenate synthetase. The enzymes are related to the nongrowing state of Mycobacterium tuberculosis. Salicylanilide diethyl phosphates represent new candidates with significant inhibitory activity especially against L-alanine dehydrogenase. The most active MtAlaDH inhibitor, 5-chloro-2-[(3-chlorophenyl)carbamoyl]phenyl diethyl phosphate, has an IC50 of 4.96 µM and the best docking results. Other mycobacterial enzymes were mostly inhibited by some derivatives but at higher concentrations; isocitrate lyase showed the highest resistance to salicylanilide diethyl phosphates.
- 650 _2
- $a antituberkulotika $x chemie $7 D000995
- 650 12
- $a bakteriální proteiny $x antagonisté a inhibitory $x chemie $7 D001426
- 650 _2
- $a inhibitory enzymů $x chemie $7 D004791
- 650 12
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a Mycobacterium tuberculosis $x enzymologie $7 D009169
- 650 _2
- $a salicylanilidy $x chemie $7 D012458
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Novotná, Eva $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 700 1_
- $a Saxena, Shalini $u Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Hyderabad 500078, India.
- 700 1_
- $a Yogeeswari, Perumal $u Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Hyderabad 500078, India.
- 700 1_
- $a Sriram, Dharmarajan $u Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Hyderabad 500078, India.
- 700 1_
- $a Švarcová, Markéta $u Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 700 1_
- $a Vinšová, Jarmila, $u Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. $d 1951- $7 nlk19990073991
- 773 0_
- $w MED00181094 $t TheScientificWorldJournal $x 1537-744X $g Roč. 2014, č. - (2014), s. 703053
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25538961 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20181212134316 $b ABA008
- 999 __
- $a ok $b bmc $g 1102706 $s 924631
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 2014 $c - $d 703053 $e 20141104 $i 1537-744X $m TheScientificWorldJournal $n ScientificWorldJournal $x MED00181094
- GRA __
- $a NT13346 $p MZ0
- LZP __
- $a Pubmed-20160108